Biportal vs. Multiportal robotic surgery for lung cancer resection
Official title: Clinical Trial in Patients With Non-Small Cell Lung Cancer Undergoing Biportal Versus Multiportal Robotic Thoracic Surgery: Comparison of Two Innovative Techniques
Run by Hospital Universitari de Bellvitge · NCT07818135 · Data updated 2026-11-12
This study tests whether a two-incision robotic approach (biRATS) works as well as the standard multiple-incision approach (multiRATS) for removing lung tumors in adults with NSCLC.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | Hospital Universitari de Bellvitge Academic / other |
| Locations | 1 site (L'Hospitalet de Llobregat, Barcelona) |
| Status | Recruiting |
| Started | January 15, 2026 |
| Main results expected | February 2028 |
| Study ends | February 2028 |
| Registry record updated | September 14, 2026 |
| Trial ID | NCT07818135 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 or older with NSCLC considered resectable and suitable for robotic pulmonary resection, who can consent and participate in long-term follow-up.
✕Probably not a fit
Patients with non-resectable disease, thoracic anatomy unsuitable for robotic approaches, or who do not receive the assigned robotic technique may not experience benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center randomized trial compares biRATS and multiRATS in adults with resectable NSCLC undergoing robotic pulmonary resection. Participants are randomly assigned to either biRATS or multiRATS, with partial blinding of postoperative dressing. The study collects intraoperative and early postoperative safety data, as well as blood loss, need for conversion, chest-drain duration, length of stay, pain, readmission, mortality, and health-related quality of life over 12 months. Quality of life is measured with EQ-5D-5L, EORTC QLQ-C30, and EORTC QLQ-LC13; pain with a visual analog scale and DN4. Follow-up occurs during hospitalization and at 1, 6, and 12 months post-surgery.
Why it matters
Potential benefit: If biRATS shows similar safety with better ergonomic access and patient-reported outcomes, patients may benefit from comparable surgical results with potentially improved recovery.
How similar studies have gone: Robotic-assisted thoracic surgery comparisons have shown feasibility and safety, but head-to-head randomization between biRATS and multiRATS is innovative with limited prior results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 18 years or older, of any sex. * Non-small cell lung cancer considered clinically resectable, confirmed preoperatively or during surgery. * Candidate for pulmonary resection by robotic thoracic surgery. * Written informed consent. Exclusion Criteria: * Declines participation or cannot provide written informed consent. * Thoracic anatomical abnormalities that preclude or materially affect robotic surgery. * Active thoracic infection. * Surgery not performed by a participating surgeon with comparable experience in biRATS and multiRATS.
Where it's running
-
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain Recruiting
Study contacts
- Principal investigator: Carlos Déniz Armengol, MD, PhD — Hospital Universitari de Bellvitge
- Study coordinator: Carlos Déniz Armengol, MD, PhD
- Email: cjdeniz@bellvitgehospital.cat
- Phone: +34 932607500
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Patient-specific MRD liquid biopsy for resected NSCLC
This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.
-
Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases
This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.
-
Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies
This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery
This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.
-
HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC
This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.